# INOPASE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inopase

- Industry: Medical Devices & Equipment
- Headquarters: Tokyo, Japan
- Website: www.inopase.com/
- Latest round: Seed (Sep 3, 2024)
- Investors on record: 4

## About

Founded in 2021 and based in Tokyo, Japan, INOPASE Inc. operates and develops medical devices related to closed-loop nerve stimulation therapy, a radical treatment for chronic neurological diseases. In September 2024, the firm raised an amount in venture funding from investors Lifetime Ventures, Mitsubishi UFJ Capital, FFG Venture Business Partners, and Join & Venture GmbH. Wang Yen Po and Munemasa Sugimoto co-founded the firm, and led it as CEO, as of 2024.

The company offers Closed-Loop Sacral Neuromodulation and Closed-Loop Brain Neuromodulation for chronic neurological diseases. INOPASE's products utilize algorithms for closed-loop neuromodulation, allowing real-time adjustments to stimulation therapy based on neural activity. These technologies target conditions such as drug-resistant epilepsy and overactive bladder, offering patients new avenues for relief and improved functionality.

The September 2024 funding may be used to proceed with clinical PoC studies, strengthen the patent network, and expand overseas business.

## Funding rounds

- Seed, Sep 3, 2024 — Mitsubishi UFJ Capital, Join & Venture GmbH, FFG Venture Business Partners, Lifetime Ventures

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Seed
- Join & Venture GmbH — Seed
- FFG Venture Business Partners (https://capitalatlas.ai/funds/ffg-venture-business-partners) — Seed
- Lifetime Ventures (https://capitalatlas.ai/funds/lifetime-ventures) — Seed